← Back to Screener
AIM ImmunoTech Inc. (AIM)
Price$0.49
Favorite Metrics
Price vs S&P 500 (26W)-86.40%
Price vs S&P 500 (4W)-52.70%
Market Capitalization$4.44M
All Metrics
Book Value / Share (Quarterly)$4.96
P/TBV (Annual)2.71x
Revenue Growth (3Y)-14.54%
Cash Flow / Share (Quarterly)$-3.69
Price vs S&P 500 (YTD)-54.57%
Gross Margin (TTM)-45.45%
Net Profit Margin (TTM)-15861.36%
EPS (TTM)$-11.96
10-Day Avg Trading Volume0.37M
EPS Excl Extra (TTM)$-11.96
Revenue Growth (5Y)-11.60%
EPS (Annual)$-8.62
ROI (Annual)-283.00%
Gross Margin (Annual)-45.45%
Net Profit Margin (5Y Avg)-13669.23%
Cash / Share (Quarterly)$0.99
Revenue Growth QoQ (YoY)-53.33%
ROA (Last FY)-241.40%
Revenue Growth TTM (YoY)-48.24%
EBITD / Share (TTM)$-7.49
ROE (5Y Avg)-92.13%
Operating Margin (TTM)-13254.55%
Cash Flow / Share (Annual)$-3.69
P/B Ratio1.53x
P/B Ratio (Quarterly)5.44x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)67.42x
Net Interest Coverage (TTM)-6.50x
ROA (TTM)-257.85%
EV / EBITDA (TTM)1.43x
EPS Incl Extra (Annual)$-8.62
Current Ratio (Annual)0.53x
Quick Ratio (Quarterly)0.49x
3-Month Avg Trading Volume3.21M
52-Week Price Return-81.26%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.65
P/S Ratio (Annual)50.48x
Asset Turnover (Annual)0.02x
52-Week High$19.74
Operating Margin (5Y Avg)-14153.95%
EPS Excl Extra (Annual)$-8.62
CapEx CAGR (5Y)-8.67%
Tangible BV CAGR (5Y)13.20%
26-Week Price Return-77.66%
Quick Ratio (Annual)0.49x
13-Week Price Return-57.07%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.53x
Enterprise Value$5.933
Revenue / Share Growth (5Y)60.55%
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)34.84%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.67x
Pretax Margin (Annual)-15861.36%
Cash / Share (Annual)$0.99
3-Month Return Std Dev185.27%
Gross Margin (5Y Avg)-62.82%
Net Income / Employee (TTM)$-1
ROE (Last FY)-283.00%
Net Interest Coverage (Annual)-6.50x
EPS Basic Excl Extra (Annual)$-8.62
Receivables Turnover (TTM)12.18x
Total Debt / Equity (Quarterly)0.94x
EPS Incl Extra (TTM)$-11.96
Receivables Turnover (Annual)0.14x
ROI (TTM)-298.96%
P/S Ratio (TTM)50.48x
Pretax Margin (5Y Avg)-13669.23%
Revenue / Share (Annual)$0.05
Tangible BV / Share (Annual)$16.12
Price vs S&P 500 (52W)-116.36%
Year-to-Date Return-50.44%
5-Day Price Return2.67%
EPS Normalized (Annual)$-8.62
ROA (5Y Avg)-134.65%
Net Profit Margin (Annual)-15861.36%
Month-to-Date Return-7.59%
Cash Flow / Share (TTM)$-0.42
EBITD / Share (Annual)$-7.45
Operating Margin (Annual)-13254.55%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-87.54%
LT Debt / Equity (Quarterly)0.05x
EPS Basic Excl Extra (TTM)$-11.96
P/TBV (Quarterly)41.69x
P/B Ratio (Annual)2.10x
Inventory Turnover (TTM)1.67x
Pretax Margin (TTM)-15861.36%
Book Value / Share (Annual)$20.82
Price vs S&P 500 (13W)-59.94%
Beta1.34x
Revenue / Share (TTM)$0.03
ROE (TTM)-397.59%
52-Week Low$0.51
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AIMAIM ImmunoTech Inc. | 50.48x | -48.24% | -45.45% | — | $0.49 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
AIM ImmunoTech is an immunotherapy company developing treatments for cancer, viral infections, and immune disorders. Its lead asset, Ampligen (rintatolimod), a novel double-stranded RNA therapeutic, is approved for commercial sale in Argentina for severe chronic fatigue syndrome. The company also markets Alferon N Injection (Interferon alfa).